Will you also do an analysis? There's going to be a year lead time going into it, so some companies will obviously be making decisions, and patients are going to be waiting for some of these drugs. They're seeing their friends and people they know travelling to America. Trikafta is a perfect example, because it happens all the time. I just spoke with a patient who is on Trikafta through SAP in Canada, and it's a life-changing experience for her.
How are we going to track situations like hers, where people can't get access to SAP or, after it's approved—if it is approved—are not eligible for it? How will you track that? Will they be part of those metrics showing that these people didn't get access to it?